Lim, Wah-Seng <br/><br/>
Schedule- and dose-dependency of CPX-351, a synergistic fixed ratio cytarabine:daunorubicin formulation, in consolidation treatment against human leukemia xenografts.  [electronic resource] 

 -  Leukemia & lymphoma  Aug 2010 
 - 1536-42 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1029-2403 
<br/><br/><label>Standard No.: </label>10.3109/10428194.2010.490312  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Combined Chemotherapy Protocols--pharmacokinetics<br/>Bone Marrow Cells--drug effects<br/>Chemistry, Pharmaceutical<br/>Cytarabine--administration & dosage<br/>DNA-Binding Proteins--physiology<br/>Daunorubicin--administration & dosage<br/>Dosage Forms<br/>Dose-Response Relationship, Drug<br/>Drug Administration Schedule<br/>Drug Synergism<br/>Female<br/>Flow Cytometry<br/>Humans<br/>Liposomes<br/>Maximum Tolerated Dose<br/>Mice<br/>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma--drug therapy<br/>Survival Rate<br/>Tissue Distribution<br/>Tumor Cells, Cultured<br/>Xenograft Model Antitumor Assays